Health Canada and the European Medicines Agency publish clinical data used to support their authorizations of the Moderna COVID-19 vaccine
March 2, 2021 | Ottawa, Ontario | Health Canada
Openness and transparency are key to building confidence in COVID-19 vaccines. Today, Health Canada and the European Medicines Agency (EMA) collaboratively published the full clinical data reviewed as part of their authorizations of the Moderna COVID-19 vaccine.
This international partnership highlights the shared commitment of both organizations to ensure the public has as much information as possible to make decisions regarding vaccination. Increasing access to clinical data can also have widespread benefits for the health care system and the research community. Health Canada and the EMA are the only two jurisdictions in the world publishing this comprehensive information.
“Health Canada is committed to openness and transparency. By releasing the clinical data behind the Moderna COVID-19 vaccine submission, Canada and the EMA are providing the healthcare community and researchers with a tremendous resource they can use to help bring the COVID-19 pandemic under control,” said Pierre Sabourin, Assistant Deputy Minister of Health Canada.
“With the publication of the data package for Moderna’s COVID-19 vaccine, we are publishing the clinical reports that we assessed in support of the authorization of this vaccine, and going forward, we will continue with this open data approach for all other COVID-19 vaccines,” said Emer Cooke, EMA’s Executive Director. “EMA and Health Canada’s joint commitment to openness and transparency will support global research, allow for public scrutiny and reinforce society’s trust in COVID-19 vaccines as mass vaccination campaigns continue to be rolled out across the EU, Canada and the rest of the world.”
The EMA and Health Canada are working together with manufacturers to expedite the publication of clinical information underpinning their authorizations for medicines and vaccines for COVID-19. The clinical data for the Pfizer-BioNTech COVID-19 vaccine is expected to be published shortly.
The publication of clinical data for these vaccines is part of the exceptional measures taken by the EMA, and the commitments made by Health Canada, to maximize the transparency of regulatory activities on treatments and vaccines for COVID-19 that are authorized or under evaluation. It is in line with the EMA’s landmark policy launched in 2016 to proactively publish clinical data supporting marketing authorization applications, and Health Canada’s clinical transparency initiative which followed in 2019.
The clinical data package for the Moderna COVID-19 vaccine, presenting the interim safety and efficacy data generated in three clinical studies, is available on the EMA's clinical data website and Health Canada’s Public Release of Clinical Information portal.
The data anonymization report is also available on the EMA’s clinical data website. It provides an explanation of the methods used to protect personal data in the clinical reports.
COVID-19 information line:
Report a problem or mistake on this page
- Date modified: